Introduction
============

Mutations in the STAM binding protein (STAMBP) gene cause microcephaly-capillary malformation (MIC-CAP) syndrome (OMIM, 614261; ORPHA, 294016), which was described as a novel syndrome several years ago ([@b1-mmr-20-06-5145],[@b2-mmr-20-06-5145]). Elevated ubiquitin-conjugated protein aggregation and apoptosis activation has previously been identified in lymphoblastoid cell lines from patients with MIC-CAP caused by *STAMBP* mutations. Additionally, elevated autophagosome content, active and insensitive RAS-MAPK and PI3K-AKT-mTOR pathways have also been found in this syndrome ([@b1-mmr-20-06-5145]). The MIC-CAP syndrome is a rare neurocutaneous disorder characterized by congenital microcephaly, early-onset epilepsy, severe profound developmental delay and diffuse cutaneous capillary malformations ([@b1-mmr-20-06-5145]--[@b3-mmr-20-06-5145]). In total, 18 pathogenic mutations have been reported in 16 patients from 8 ethnic groups ([@b1-mmr-20-06-5145]--[@b8-mmr-20-06-5145]).

To the best of our knowledge, the present study reported the case of the first Chinese patient with MIC-CAP syndrome caused by a novel compound heterozygous *STAMBP* mutation. The present study also provided a review of relevant previously published cases.

Patients and methods
====================

### Patients

Ethical approval for the present study was obtained from the Institutional Review Board, Children\'s Hospital of Chongqing Medical University (permit no. 2018-64). Informed consent was obtained from the parents of the patient.

The case described in the present study is that of a boy born after 40 weeks and 5 days of gestation, G2P1 (second pregnancy and first successful birth of the mother), to nonconsanguineous Chinese parents (father, 23 years old; mother, 22 years old). The boy was born through normal delivery, with a birth weight of 3,600 g. The birth length and head circumference were not known.

The patient was admitted (June 2018) to the Department of Neurology, Children\'s Hospital of Chongqing Medical University at the age of 1 year and 5 months. A routine examination of general health and neurological evaluations were carried out. Magnetic resonance imaging (MRI), electroencephalography and metabolic screening were performed according to the manufacturer\'s protocols. All the available clinical characteristics of the patient along with the aforementioned auxiliary examination results are summarized in the present study.

### Genetic analysis

Peripheral blood samples (5 ml) from the proband and the parents were collected into graded negative pressure vacuum EDTA anticoagulant tubes. All sample preparation, whole-exome sequencing and Sanger sequencing were performed by Beijing Mygenostics Co, Ltd. Several online databases containing data from different ethnic groups were used as following; dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), ExAC (<http://exac.broadinstitute.org/faq>), Genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org/>), Clinvar (<https://www.ncbi.nlm.nih.gov/clinvar/>), esp6500siv2_all (<http://evs.gs.washington.edu/EVS/>). 1000 genome (<http://www.1000genomes.org>), Mutation screening of *STAMBP* was performed using Sanger sequencing with two primer pairs to amplify exon 9 (chr2-74087178) and exon 7 (chr2-74077603) of the STAMBP gene (NM_201647). The following primers were used: Exon 9, forward 5′-CTCACAATGACCTCTGCCCT-3′, reverse 5′ATTCCTGTCCCACACTGCTT-3′; and exon 7, forward 5′GAGCACCAGGGAATTGTGAC-3′ and reverse 5′AAGCCCTAAGTGTTCCCAGA-3′. BigDye Terminator v3.1 Cycle Sequencing kit (Invitrogen; Thermo Fisher Scientific, Inc.) was used and thermal cycling was performed in a Mix Golden Star T6 Super PCR Mix (1.1×; TsingKe Biological Technology Co.; [Table I](#tI-mmr-20-06-5145){ref-type="table"}). The segregation of the identified mutations was investigated in the parents.

The prediction of mutations was assessed using software, including PolyPhen_2\_Predict, PolyPhen_2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT, SIFT_Predict (<http://sift.jcvi.org/>), SPIDEX (<http://www.deepgenomics.com/spidex>), MutationTaster, MutationTaster_Predict (<http://www.mutationtaster.org/ChrPos.html>), MCAP_score, MCAP_pred (<http://bejerano.stanford.edu/MCAP/>), GERP++\_Predict, GERP++ (<http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html>) and REVEL_score (<https://sites.google.com/site/revelgenomics/>). The protein structure of *STAMBP* was modelled using the SWISS-MODEL (3rzv.1, <http://swissmodel.expasy.org/interactive>)

### Literature review

The PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>) and Wanfang (<http://www.wanfangdata.com.cn/index.html>) databases were used to retrieve previous studies using the keywords 'STAMBP, microcephaly, and capillary malformation' until April 2019. The publication language was limited to English and Chinese.

Results
=======

### Patient treatment

The child developed early-onset epilepsy after 3 months, with a generalized tonic-clonic seizure, which progressed to clusters of infantile spasms (2--10 clusters/day) 1 month later. The patient was treated successively with levetiracetam (40--50 mg/kg/day), topiramate (6--7 mg/kg/day), valproic acid (30 mg/kg/day) and corticosteroids at the outpatient clinic. The spasms decreased and became myoclonic, but the epilepsy remained refractory.

The patient was admitted to the neurologic ward after 1 year and 2 months. The patient had drooping mouth corners, a short nose and neck, and sporadic, multiple, small capillary malformations ([Fig. 1A and B](#f1-mmr-20-06-5145){ref-type="fig"}). Referring to the World Health Organization Anthro standards (<https://www.who.int/childgrowth/software/en/>), the patient was 8 kg \[*Z*-score, −2.8 Standard Deviation (SD)\] in weight and 63 cm (*Z*-score, −6.8 SD) in length. The head circumference was 39.5 cm (*Z*-score, −5.8 SD). The boy could not hold his head and had prominent dyskinesia of the whole body, particularly involuntary movement of the tongue and mouth ([Video S1](#SD2-mmr-20-06-5145){ref-type="supplementary-material"}).

The patient was on a ketogenic diet during the inpatient stay and received immunoglobulin intravenously as a result of recurrent pneumonia, 22 days later, he was discharged. During the follow-up, the seizures were still not well controlled, although the ketogenic diet ratio was modified from 2:1 to 4:1 (4 g fat/l g combined protein, carbohydrate). After 1 month, the patient received vigabatrin (60 mg/kg/day) and the seizures reduced by 80% a week later. Unfortunately, the patient suddenly succumbed 3 weeks later; no definitive causes were found as no autopsy was performed.

The MRI scans showed slightly dilated lateral ventricles and increased extra-axial spaces. Interictal electroencephalography showed hypsarrhythmia and slow wave background with bioccipital spike-slow wave during waking ([Fig. 1C and D](#f1-mmr-20-06-5145){ref-type="fig"}). Blood and urinary metabolic screening indicated normal results.

### Exome sequencing

Exome sequencing revealed intronic (c.1119-1G\>T) and exonic mutations in the proband and their parents, which was confirmed via Sanger sequencing ([Fig. 2A](#f2-mmr-20-06-5145){ref-type="fig"}). The mutations segregated according to a strictly recessive model with full penetrance. The parents were found to be heterozygous carriers, (mother, c.1119-1G\>T; father, c.968A\>G; [Fig. 2A](#f2-mmr-20-06-5145){ref-type="fig"}). The protein structures of wild-type and mutated *STAMBP* were modelled and predicted, respectively, as shown in [Fig. S1](#SD1-mmr-20-06-5145){ref-type="supplementary-material"}. The mutations affected the amino acid side chain (p.Gln323Arg) and were predicted to be pathogenic. The splice site variant (c.1119-1G\>T) was predicted to generate aberrant splicing of the *STAMBP* mRNA.

The clinical features and pathogenic variants of 16 previously reported cases of MIC-CAP are summarized in [Table II](#tII-mmr-20-06-5145){ref-type="table"} and [Fig. 2B](#f2-mmr-20-06-5145){ref-type="fig"}.

Discussion
==========

So far as we know, the present study presented the first case of a Chinese patient affected by refractory epilepsy, microcephaly, severe developmental delay and diffuse cutaneous capillary malformations. These four symptoms were also observed in all of the patients studied in previous reports (100%) ([@b1-mmr-20-06-5145]--[@b8-mmr-20-06-5145]). The patient in the present study also had spastic quadriparesis, without optic atrophy; however, both optic atrophy and spastic quadriparesis were common in previous cases ([@b1-mmr-20-06-5145]--[@b8-mmr-20-06-5145]). Moreover, dyskinesia was more prominent in the present study and was infrequent in previous cases, except in one patient ([@b1-mmr-20-06-5145]). Although the patient in the present study responded well to vigabatrin, the long-term efficacy of the drug could not be evaluated due to the early death of the patient.

A novel compound heterozygous co-segregating mutation in *STAMBP* \[c.1119-1G\>T (splicing, exon9, maternal allele) and c.968A\>G (p.Gln323Arg, exon7, paternal allele); [Fig. 2A](#f2-mmr-20-06-5145){ref-type="fig"}\] was identified through exome sequencing. The parents of the patient were healthy. The variant frequency of the aforementioned mutation has not been reported in the Chinese Reference Genome Database or any public sequence database, to the best of our knowledge. *In silico* analysis indicated that this splice site mutation generated aberrant splicing of the STAMBP mRNA, and c.968A\>G was also predicted to be pathogenic. Therefore, a definite diagnosis for this patient with MIC-CAP could be made due to the autosomal recessive inheritance patterns, according to the previous reports ([@b1-mmr-20-06-5145]--[@b8-mmr-20-06-5145]).

To date, only 16 cases (11 male and 5 female) from 13 families in 8 ethnic groups have been reported, with 18 different *STAMBP* mutations ([@b1-mmr-20-06-5145]--[@b8-mmr-20-06-5145]). All the parents were from unrelated families, except for two consanguineous relationships ([@b4-mmr-20-06-5145]--[@b6-mmr-20-06-5145]). A further two patients had causative mutations (c.753_754insT, c.1119-1G\>T) ([@b6-mmr-20-06-5145],[@b8-mmr-20-06-5145]), which have been omitted from the figure as further details of these patients could not be found. In total,\~20 *STAMBP* mutations are listed online without further patient details; therefore, their pathogenicity could not be confirmed (ClinVar).

In conclusion, to the best of our knowledge, the present study reported the first case of a Chinese patient with refractory epilepsy as an initial symptom of MIC-CAP. Additionally, novel pathogenic compound heterozygosity of the *STAMBP* was identified. The results of the present study may improve understanding of *STAMBP* mutations and ethnic background in cases MIC-CAP.
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###### 

Case presentation. Sporadic multiple small capillary malformations (black arrows) found on the (A) forehead and (B) upper back. At the age of 12 months, interictal electroencephalogram revealed hypsarrhythmia (C), and slow wave background with bioccipital spike slow wave (D) during waking.

![](MMR-20-06-5145-g00)

![](MMR-20-06-5145-g01)

![Pedigreeof the family. (A) Sanger sequencing showing a novel *STAMBP* compound heterozygosity mutation inherited from the parents. (B) Gene structure of *STAMBP*, and its pathogenic variants in patients with microcephaly-capillary malformation reported previously and described in the present study (red). CH, compound heterozygous; *STAMBP*, encodes STAM binding protein.](MMR-20-06-5145-g02){#f2-mmr-20-06-5145}

###### 

Thermocycling conditions for Sanger sequencing.

  Step   Temperature (°C)   Time     Cycle
  ------ ------------------ -------- -------
  1      95                 10 min   1
  2      94                 30 sec   3
         64                 30 sec   
         72                 45 sec   
  3      94                 30 sec   5
         62                 30 sec   
         72                 45 sec   
  4      94                 30 sec   10
         60                 30 sec   
         72                 45 sec   
  5      94                 30 sec   17
         58                 30 sec   
         72                 45 sec   
  6      72                 5 min    1
  7      4                  Holds    

###### 

Summary of the patient and 16 previously reported MIC-CAP cases caused by STAMBP mutations.

  Patients                                                                  1                                                                                                     2                                                                                                     3                                                                                                     4                                                                                                     5                                                                                                    6                                                                                                     7                                                     8                                                                                                     9
  ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Basic characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    Reference                                                               This study                                                                                                                                                                                                                                                                                                                                                                                                              McDonell *et al* 2013                                                                                                                                                                                                                                                                                                                                                  
    Gender                                                                  M                                                                                                     F                                                                                                     M                                                                                                     M                                                                                                     M                                                                                                    M                                                                                                     F                                                     M                                                                                                     F
    Age                                                                     1 year 3 months                                                                                       2 years                                                                                               9 months                                                                                              12 months                                                                                             2 years                                                                                              22 days                                                                                               5 years 4 months                                      2 months                                                                                              28 months
    Ethnicity                                                               Chinese                                                                                               African-American                                                                                      ED                                                                                                    European                                                                                              European                                                                                             European                                                                                              European                                              European                                                                                              
    GA, BW (weeks, SD or g)                                                 40^+5^, 3,600                                                                                         39, −1.5                                                                                              39, −1.5                                                                                              36^+5^, −1.5                                                                                          36, −2                                                                                               37, −2                                                                                                Term, +1.8                                            36, −1.5                                                                                              37^+2^, −4
  Symptoms and signs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    Microcephaly                                                            \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    \+
    Capillary malformations                                                 \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    \+
    Dysmorphic appearance^[a](#tfn3-mmr-20-06-5145){ref-type="table-fn"}^     +^1,4^                                                                                              \+^3^                                                                                                   +^3^                                                                                                −                                                                                                       +^3^                                                                                                 +^3^                                                                                                  +^3^                                                  +^3^                                                                                                  +^3^
    IE (age of onset)                                                       +(3 months)                                                                                           +(NA)                                                                                                 +(NA)                                                                                                 +(NA)                                                                                                 +(NA)                                                                                                +(NA)                                                                                                 +(NA)                                                 +(NA)                                                                                                 \+
    Infantile spasms                                                        \+                                                                                                    \+                                                                                                    −                                                                                                     \+                                                                                                    −                                                                                                    −                                                                                                     −                                                     −                                                                                                     NA
    Myoclonus                                                               \+                                                                                                    −                                                                                                     \+                                                                                                    \+                                                                                                    \+                                                                                                   −                                                                                                     −                                                     \+                                                                                                    \+
    Developmental delay                                                     \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    \+
    Spastic quadriparesis                                                   \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    −                                                     −                                                                                                     \+
    Optic atrophy                                                           NA                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    NA                                                    NA                                                                                                    \+
    Dyskinesia                                                              \+                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                   NA                                                                                                    NA                                                    NA                                                                                                    NA
  Auxiliary examination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    Neuroimaging features^[b](#tfn4-mmr-20-06-5145){ref-type="table-fn"}^     +^[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^                                                     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"},[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^   −                                                       +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^
    EEG anomalies                                                           \+                                                                                                    Presumed+^[f](#tfn8-mmr-20-06-5145){ref-type="table-fn"}^                                             Presumed +                                                                                            Presumed +                                                                                            Presumed +                                                                                           Presumed +                                                                                            Presumed +                                            Presumed +                                                                                            Presumed +
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Patient**                                                               **10**                                                                                                **11**                                                                                                **12**                                                                                                **13**                                                                                                **14**                                                                                               **15**                                                                                                **16**                                                **17**                                                                                                **Total**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Basic characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    Reference                                                               McDonell *et al* 2013                                                                                 Faqeih *et al* 2015                                                                                   Naseer *et al* 2016                                                                                   Hori *et al* 2018                                                                                     Demikova *et al* 2018                                                                                                                                                                                                                                                                                                                                                  
    Gender                                                                  F                                                                                                     M                                                                                                     M                                                                                                     M                                                                                                     M                                                                                                    M                                                                                                     M                                                     F                                                                                                     5 F/12 M
    Age                                                                     8 months                                                                                              15 months                                                                                             8 years 6 months                                                                                      5 years                                                                                               NA                                                                                                   NA                                                                                                    2 years                                               6 months                                                                                              
    Ethnicity                                                               Polynesian                                                                                            ED                                                                                                    Arabic                                                                                                                                                                                                      Egyptian                                                                                                                                                                                                   Japanese                                              Russia                                                                                                9
    GA, BW (weeks, SD or g)                                                 37^+6^, −1.5                                                                                          35, −1.5                                                                                              Term. 2,600                                                                                           NA, 2,800                                                                                             NA                                                                                                   NA                                                                                                    37, 2,680                                             30, 2,250                                                                                             
  Symptoms and signs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    Microcephaly                                                            \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    17 (100%)
    CM                                                                      \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    17 (100%)
    Dysmorphic appearance                                                     +^3^                                                                                                  +^3^                                                                                                  +^1,2^                                                                                                +^1,2,3^                                                                                              +^1,2,3^                                                                                             +^1,2,3^                                                                                              +^1,2,4^                                              +^1,4^                                                                                              17 (100%)
    IE (age of onset)                                                       \+                                                                                                    \+                                                                                                    +(7 months)                                                                                           +(7 months)                                                                                           +(Infancy)                                                                                           +(Infancy)                                                                                            +(7 months)                                           +(2 months)                                                                                           17 (100%)
    Infantile spasms                                                        \+                                                                                                    \+                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                   NA                                                                                                    \+                                                    \+                                                                                                      7 (41.2%)
    Myoclonus                                                               NA                                                                                                    \+                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                   NA                                                                                                    NA                                                    \+                                                                                                      8 (47.1%)
    Developmental delay                                                     \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                    17 (100%)
    Spastic quadriparesis                                                   \+                                                                                                    \+                                                                                                    \+                                                                                                    \+                                                                                                    NA                                                                                                   NA                                                                                                    −                                                     \+                                                                                                      12 (70.1%)
    Optic atrophy                                                           −                                                                                                     −                                                                                                     \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    −                                                     NA                                                                                                      10 (58.8%)
    Dyskinesia                                                              \+                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                    NA                                                                                                   NA                                                                                                    NA                                                    NA                                                                                                      2 (11.2%)
  Auxiliary examination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    Neuroimaging features                                                     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"}--[e](#tfn7-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"},[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^      +^[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^                                                     +^[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^                                                     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"},[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^     +^[c](#tfn5-mmr-20-06-5145){ref-type="table-fn"},[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^      +^[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^     +^[d](#tfn6-mmr-20-06-5145){ref-type="table-fn"}^                                                     16 (94.1%)
    EEG anomalies                                                           Presumed +                                                                                            Presumed +                                                                                            \+                                                                                                    \+                                                                                                    \+                                                                                                   \+                                                                                                    \+                                                    \+                                                                                                      17 (100%)

P2 and P3, P12 and P13, and P14 and P15 were siblings. P12 and P13, and P14 and P15 were born to parents from consanguineous marriage.

Dysmorphic appearance: 1widely spaced eyes; ^2^long palpebral fissures; ^3^underdeveloped distal phalanges; ^4^downturned mouth.

Neuroimaging features:

simplified gyral pattern

cerebral atrophy/increased extra-axial space

hippocampal hypoplasia.

Presumed +: These cases had intractable epilepsy but without detailed EEG data. BW, birth weight; CM, capillary malformations; EEG, electroencephalography; ED, European descent; GA, gestational age; IE, intractable epilepsy, NA, not available.

[^1]: Contributed equally
